Reply by Villa, E et al.
Replay 1607
British Journal of Cancer (2001) 85(10), 1606–1608 © 2001 Cancer Research Campaign
some instances, favourably influence the course of the disease,
but that this, in a consecutive series of HCC patients, happens in a
small minority of cases, the treatment being purely palliative in a
relatively larger sub-group and of no use in the majority. This,
since the variant receptor is to be detected in HbsAg positive
patients (Villa et al, 1998), may well have something to do with
the fact that we, by now, see mostly patients with HCV-related
chronic liver damage and HCC. On the other hand, in four
patients development of portal or deep venous thrombosis was
observed, which could be considered an expected worsening in
patients with HCC, with respect to portal thrombosis, but that
could have something to do with the pro-coagulant properties of
megestrol at least in the case of deep venous damage (Force et al,
1999). Our experience therefore, albeit limited and uncontrolled,
suggests that side effects, particularly on blood coagulation, may
not be irrelevant. 
In summary, our feeling is that megestrol and the variant
oestrogen receptor may be more a step in the understanding of
the patho-physiological mechanisms underlying HCC develop-
ment and progression than a true advance in HCC treatment but
we are available to change our mind if new additional data will
confirm those reported by Villa et al (2001) and deny our find-
ings. This is also because the tamoxifen story has taught
everyone, and us more than others, that preliminary, successful
small size trials are to be confirmed by large size prospective
randomized placebo-controlled studies before a drug enters
routine clinical practice. 
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Reply
Sir, 
Dr Farinati and colleagues have reported an uncontrolled experi-
ence with megestrol in the treatment of inoperable hepatocellular
carcinoma. Their results were somewhat different from those we
have reported in Br J Cancer (Villa et al, 2001) and we would like
to add some considerations. 
Despite the fact that megestrol has a rationale in HCC charac-
terised by both wild-type and variant oestrogen receptors (vERs),
as its action is displayed at post-receptorial level (and therefore
able to interfere both vERs and wild-type ERs (wtERs), still the
natural history of HCC with wtERs is so favourable and the
growth speed of the tumours so slow that megestrol or any other
antihormonal drug, would not add much in terms of amelioration
of prognosis (Villa et al, 2000). The choice of treating with mege-
strol only patients with vERs was therefore justified by the much
more aggressive clinical course of these HCCs, which could allow
easier identification of any effect on tumour growth or an improve-
ment in survival. As variant ERs are usually not more than 30% of
patients with HCC, the higher percentage of patients with wild-
type ERs could obscure a favourable effect of megestrol when this
treatment is used in a mixed population. 
Furthermore, the uncontrolled design of the study by Farinati
et al, could not allow perception of the most relevant finding of our
study, i.e. the improvement in survival in treated patients. It was,
in fact, already evident from our data that megestrol did not deter-
mine regression of tumour mass (except in a few cases) whereas
slowing down of tumour growth was remarkable in comparison
with untreated patients. This effect was short-lived but sufficient
to determine a significant improvement of survival at 1 year (Villa
et al, 2001). Certainly, megestrol was not powerful enough to cure
HCC, but in these patients with ominous prognosis, a gain of
10–12 months in survival can be considered an achievement. In a
few of them, clinical improvement was also accompanied by
significant regression of tumour mass which allowed performance
of radical treatment (E Villa and V Mazzaferro, personal commu-
nication). 
Last but not least, the side effects reported by Farinati et al (e.g.
portal vein thrombosis, deep vein thrombosis, bleeding etc.) may
also spontaneously occur in HCC patients: again the uncontrolled
experimental design by Farinati was certainly not suitable for
correctly allocating side effects to therapy or to disease. Indeed,
in our series increase in appetite and in weight occurred in a
remarkable percentage of treated patients and in none of the
control. However, as for the vascular complications, deep vein
thrombosis occurred in the same proportion in treated and
untreated patients. 
In conclusion, these considerations underline the need to
observe very strict methodological rules when performing thera-
peutic trials: only a controlled method allows identification and
correct allocation of both benefits and side effects. 
E Villa, N De Maria, A Colantoni, 
M Manno and H Bertani 
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